Stock & Company Details
Allogene Therapeutics Inc $ALLO
Price:
N/A
N/A
345M
$484M
52 Week High:
N/A
10 Day Average Volume:
N/A
-1.61
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
ALLO technical indicators
Latest Allogene Therapeutics Inc (ALLO) indicator readings as of 2026-10-09.
ALLO's 14-day RSI is 29.8, in oversold territory. At $1.46 it is trading 26.8% below its 200-day moving average of $1.99, and below its 50-day average of $1.84. Price sits near the lower Bollinger Band ($1.39 to $1.83). ADX reads 42.1, indicating a trending market.
Overview
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Finance Bot
Ask your questions
Start by typing a question below.
